Eli Lilly (NYSE:LLY) Receives Overweight Rating from Cantor Fitzgerald with Increased Price Target
Lilly(US:LLY) Financial Modeling Prepยท2025-10-09 17:05Cantor Fitzgerald reaffirms its "Overweight" rating for Eli Lilly (NYSE:LLY), increasing its price target from $825 to $925.Eli Lilly partners with HealthTap to enhance its digital healthcare platform, LillyDirect, focusing on virtual diabetes management services.The addition of Peter Marks, a former top vaccine regulator, to Eli Lilly's team is expected to bolster the company's pharmaceutical innovations.Eli Lilly (NYSE:LLY) is a leading pharmaceutical company known for its innovative treatments and therap ...